|
Real-time Estimate
Cboe Europe
16:29:23 29/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 1,811.75 GBX | -1.08% |
|
-5.90% | -1.29% |
| 04:28pm | GSK plc : Gets a Neutral rating from UBS | ZD |
| 04:13pm | RBC Lowers Price Target on GSK to GBP19.25 From GBP19.75, Keeps Sector Perform Rating | MT |
Company Valuation: GSK plc
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 80,458 | 58,381 | 59,112 | 54,944 | 73,201 | 73,425 | - | - |
| Change | - | -27.44% | 1.25% | -7.05% | 33.23% | 0.31% | - | - |
| Enterprise Value (EV) 1 | 100,296 | 75,578 | 74,152 | 68,039 | 87,654 | 95,840 | 91,719 | 88,890 |
| Change | - | -24.65% | -1.89% | -8.24% | 28.83% | 9.34% | -4.3% | -3.08% |
| P/E | 18.6x | 3.93x | 11.9x | 21.3x | 12.9x | 13.6x | 11.6x | 10.9x |
| PBR | 5.34x | 5.47x | 4.4x | 4.02x | 4.51x | 4.59x | 4.06x | 3.5x |
| PEG | - | 0x | -0.2x | -0.4x | 0x | -2.92x | 0.7x | 1.56x |
| Capitalization / Revenue | 2.36x | 1.99x | 1.95x | 1.75x | 2.24x | 2.17x | 2.07x | 2x |
| EV / Revenue | 2.94x | 2.58x | 2.45x | 2.17x | 2.68x | 2.83x | 2.59x | 2.43x |
| EV / EBITDA | 8.85x | 7.23x | 6.37x | 6.36x | 7.77x | 8.34x | 7.46x | 7.04x |
| EV / EBIT | 11.4x | 9.27x | 8.44x | 7.44x | 8.96x | 9.27x | 8.28x | 7.72x |
| EV / FCF | 22.6x | 12.1x | 13.6x | 13x | 13.7x | 18.3x | 17.2x | 13.8x |
| FCF Yield | 4.42% | 8.28% | 7.36% | 7.67% | 7.32% | 5.47% | 5.81% | 7.24% |
| Dividend per Share 2 | 1 | 0.6125 | 0.58 | 0.61 | 0.66 | 0.6955 | 0.7503 | 0.7863 |
| Rate of return | 4.98% | 4.26% | 4% | 4.53% | 3.62% | 3.8% | 4.1% | 4.29% |
| EPS 2 | 1.082 | 3.662 | 1.216 | 0.632 | 1.411 | 1.345 | 1.573 | 1.683 |
| Distribution rate | 92.4% | 16.7% | 47.7% | 96.5% | 46.8% | 51.7% | 47.7% | 46.7% |
| Net sales 1 | 34,114 | 29,324 | 30,328 | 31,376 | 32,667 | 33,876 | 35,481 | 36,636 |
| EBITDA 1 | 11,330 | 10,449 | 11,635 | 10,693 | 11,278 | 11,497 | 12,292 | 12,630 |
| EBIT 1 | 8,806 | 8,151 | 8,786 | 9,148 | 9,783 | 10,342 | 11,083 | 11,512 |
| Net income 1 | 4,385 | 14,956 | 4,928 | 2,575 | 5,716 | 5,473 | 6,240 | 6,688 |
| Net Debt 1 | 19,838 | 17,197 | 15,040 | 13,095 | 14,453 | 22,415 | 18,294 | 15,465 |
| Reference price 2 | 20.08 | 14.38 | 14.50 | 13.46 | 18.24 | 18.32 | 18.32 | 18.32 |
| Nbr of stocks (in thousands) | 4,006,383 | 4,060,999 | 4,076,145 | 4,080,519 | 4,012,126 | 4,009,000 | - | - |
| Announcement Date | 2/9/22 A | 2/1/23 A | 1/31/24 A | 2/5/25 A | 2/4/26 A | - | - | - |
1GBP in Million2GBP
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 13.59x | 2.83x | 7.96x | 3.79% | 97.74B | |
| 37.84x | 13.27x | 28.43x | 0.53% | 1,148B | |
| 39.67x | 6.67x | 18.75x | 1.97% | 652B | |
| 37.4x | 8.39x | 17.35x | 2.4% | 505B | |
| 21.45x | 5.21x | 12.93x | 2.51% | 384B | |
| 102.73x | 5.76x | 24.72x | 2.42% | 348B | |
| 21.89x | 5.76x | 13.88x | 2.85% | 294B | |
| 22.21x | 4.49x | 12.82x | 1.97% | 264B | |
| 28.66x | 7.33x | 13.12x | 2.23% | 244B | |
| -45.79x | 7.11x | 27.55x | 2.07% | 197B | |
| Average | 27.97x | 6.68x | 17.75x | 2.27% | 413.49B | |
| Weighted average by Cap. | 34.77x | 8.26x | 20.34x | 1.84% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- GSK Stock
- Valuation GSK plc
Select your edition
All financial news and data tailored to specific country editions
